AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
about
Cyclin-dependent kinase inhibitor therapy for hematologic malignanciesNew molecular targets in mantle cell lymphomaTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsInduction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammationIn silico 3D structure modeling and inhibitor binding studies of human male germ cell-associated kinase.Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.Controlling the Mdm2-Mdmx-p53 Circuit.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Genome-wide localization of small molecules.A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.Molecular targeted approaches in mantle cell lymphoma.Targeting cell cycle regulators in hematologic malignancies.Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myelomaPreclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaCyclin Dependent Kinase 9 Inhibitors for Cancer TherapyCDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo.Effects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvaeDownregulation of Mcl-1 has anti-inflammatory pro-resolution effects and enhances bacterial clearance from the lungA phase I trial of flavopiridol in relapsed multiple myeloma.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Latest advances and current challenges in the treatment of multiple myeloma.Cyclin dependent kinases in cancer: potential for therapeutic intervention.Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Emerging biological insights and novel treatment strategies in multiple myeloma.Current and emerging new treatment strategies for mantle cell lymphoma.Transcription inhibition as a therapeutic target for cancerRecent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.Design and synthesis of pyrazole/isoxazole linked arylcinnamides as tubulin polymerization inhibitors and potential antiproliferative agents.Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9Pim2 is important for regulating DNA damage response in multiple myeloma cells.Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome.The therapeutic potential of cell cycle targeting in multiple myeloma.Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.
P2860
Q24561485-A1A02CAD-8944-4AB9-B14F-48FC727B629AQ26821766-4F4715B2-3130-4DD0-BC18-8C3F5215769AQ26827580-A85D0554-75FE-48A9-971C-655160F1645AQ28477314-3E510CD6-05C4-407E-9848-284E892788F0Q30367060-2E3FC156-5837-48C0-B0DF-9C0BB212420DQ31160552-64B51434-5CDA-4DE9-909A-333BB1ADBBACQ33418705-F59CBC1C-6529-422A-94C9-F5AA677F21EEQ34011009-25937CEB-FBB6-4DC5-8337-D1ED3F534BC0Q34253548-F0E9D9EF-0EC3-4BE8-ADF1-F3E28DCF6AF0Q34306973-8D35AFE4-8686-4EDE-8CE0-5B2BDFD67FA8Q34687067-8FA5927B-438D-48BE-828F-163F92E8E111Q35127368-92C485CA-7C44-4278-8F94-C406D89DDF99Q35334436-D35E1A93-7F2E-490C-9D5A-CD8DDA5468FAQ35740455-1D222F96-191D-485B-BDD0-A74B30E22197Q35915726-2AFC7A05-7286-45C5-976F-5540F4270137Q36015334-64146104-CC82-46B2-99C3-7CE0F93DCA77Q36962507-A0E43782-A924-458D-B3BD-FC67D43F8347Q37408454-FD249A7C-EC60-4647-8B4B-F39E63E6ED3EQ37467587-6D4B34B9-A3D2-4B10-9BA7-7B466248FDD5Q37613621-C6617FE3-803B-4359-8A01-C634601A81AEQ37624722-31E1BE3F-095C-4F54-B2BD-4A5295064B14Q37697253-2653FA63-220C-47D2-A2FF-A2C72514199FQ37986287-F39A045B-943C-48C7-9E3E-E3B5B3F25295Q37987789-569EFB9B-77B5-4EB9-88F4-031BEB130F36Q38008733-23584ED7-807D-4808-9605-81A11513652DQ38037600-FA53C640-8538-46AA-9EBE-4AC59D7E7EDCQ38056761-C0416982-DD27-4C25-8C5D-69A08B607C18Q38161381-487824A0-D274-4A93-8755-B231082988E4Q38806786-048C9841-4BF9-49F4-9F90-B8865F7AB6A5Q38841186-D0E4D470-8947-4FBF-948E-82F0D84D70F9Q38850709-CB3F5C13-75F3-4697-8E61-36D95AEA81F3Q38906685-BF4FCCB5-880C-4DC4-8050-86A294E7F863Q39281937-C9383E6E-C9B0-465D-B730-BF181EBFD274Q39450848-B5A097D3-E794-43E0-99BE-622F5DDF7B72Q41039819-0E17B141-C23D-48EA-AACB-412F32094223Q41963512-0E8C377E-718A-4F45-9D09-393EBEABD1AAQ42325535-BB3E77AF-1777-412D-A48B-C4533F6D8C7AQ47203904-C73DFEC2-3FD3-4427-89A1-2C6D9076B58DQ48922287-5939C7CA-49FF-4F37-9195-B47F54FFE4B6Q49514489-9232DBA0-5135-4066-BD56-F9AEDD73105A
P2860
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
AT7519, A novel small molecule ...... RNA polymerase II inhibition.
@en
type
label
AT7519, A novel small molecule ...... RNA polymerase II inhibition.
@en
prefLabel
AT7519, A novel small molecule ...... RNA polymerase II inhibition.
@en
P2093
P2860
P50
P356
P1433
P1476
AT7519, A novel small molecule ...... d RNA polymerase II inhibition
@en
P2093
E Calabrese
K C Anderson
M Boccadoro
N C Munshi
P2860
P2888
P304
P356
10.1038/ONC.2009.510
P407
P577
2010-01-25T00:00:00Z
P5875
P6179
1011776336